For example, a phase II clinical trial studying the effectiveness of the PI3K inhibitor BKM120 (NCT01629615) on metastatic TNBC patients reported that no patient achieved a complete response (CR: disappearance of tumor) nor partial response (PR: tumor shrinkage of 30%). This evidence concerns the gene PIK3CA and neoplasm.